isolated or purified peptides, pharmaceutical composition, methods to block signaling by one or more members of the cytokine-yc family, to inhibit the binding of cytokine-yc to the yc subunit and to use peptides or derivatives thereof or pharmaceutical composition, uses of isolated or purified peptides or derivatives thereof or pharmaceutical composition
isolated or purified peptides, pharmaceutical composition, methods to block signaling by one or more members of the cytokine-yc family, to inhibit the binding of cytokine-yc to the yc subunit and to use peptides or derivatives thereof or pharmaceutical composition, uses of isolated or purified peptides or derivatives thereof or pharmaceutical composition the various modalities refer to peptide antagonists of cytokines of the yc-family, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il -7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21). cytokines-yc are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). thus, inhibitors of cytokine-yc activity are valuable therapeutic and cosmetic agents, as well as research tools. traditional approaches to inhibiting cytokine-yc activity involve creating neutralizing antibodies against each individual member of the individual cytokine-yc family / receptor subunit. however, success has been limited and multiple members of the cytokine-yc family often cooperate to cause the condition. combinatorial use of neutralizing antibodies raised against each factor is impractical and presents an increased risk of adverse immune reactions. the present embodiments overcome these disadvantages by using peptide antagonists based on the consensus site of the yc subunit binding to inhibit cytokine-yc activity.peptídeos isolados ou purificados, composição farmacêutica, métodos para bloquear a sinalização por um ou mais membros da família citocina-yc, para inibir a ligação de citocinas-yc a subunidade-yc e para utilizar peptídeos ou derivados dos mesmos ou composição farmacêutica, usos de peptídeos isolados ou purificados ou derivados dos mesmos ou composição farmacêutica as várias modalidades referem-se a antagonistas peptídicos de citocinas da família-yc, interle
